Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BlackRock TCP Capital Corp (TCPC) vs Twist Bioscience Corp (TWST) Price & Performance

BlackRock TCP Capital CorpTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

BlackRock TCP Capital Corp vs Twist Bioscience Corp — how do they compare? BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 29.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold BlackRock TCP Capital Corp for 88 Days and Twist Bioscience Corp for 27 Days on average.

TCPCTWST
Market Cap
$337.71M$10.08B
Volume
436,1094,229,037
Sector
FinancialsHealth
52-Week High
$6.20$205.00
52-Week Low
$3.13$25.45
Typical Hold Time
88 Days27 Days
Enterprise Value
$1.09B$10.01B
Dividend Yield
18.88%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BlackRock TCP Capital Corp

TCPC trades at $4.035, up 2.41% today, with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 beating estimates but faces negative revenue and net income trends. Recent portfolio sales and strategic reviews aim to reduce leverage and enhance shareholder value. Analyst consensus shows 30.77% buy ratings with no sell recommendations.

Outlook remains cautious due to declining revenue and negative profitability metrics, though strategic moves may stabilize operations. Key risks include ongoing financial losses and competitive pressures in the BDC sector. Investment opportunity hinges on successful execution of portfolio optimization and debt reduction initiatives.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.

While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TCPC
0% Buy100% Sell
Avg holding period · 88 Days
TWST
100% Buy0% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About BlackRock TCP Capital Corp

BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.

Read more on TCPC →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →